The possibility of ending the AIDS pandemic and eliminating HIV as a public health threat is within reach. With over 40 million people having lost their lives to AIDS and 39 million currently living with HIV, the opportunity to see a generation grow up free of this threat is on the horizon. This would mark a historic milestone in the fight against HIV/AIDS.
The scientific advancements have made this goal achievable, backed by undeniable data. However, the real question lies in whether we have the courage to seize this opportunity. Despite significant progress in reducing AIDS-related deaths by 73% since 2002, the reality is that we are still losing a substantial number of lives to AIDS-related illnesses every day. The statistics represent real individuals – children, parents, friends, and neighbors.
While great strides have been made in providing access to HIV treatment, the area of prevention has stagnated. This is particularly concerning for adolescent girls and young women in sub-Saharan Africa, who account for the majority of new infections in their age group. The key to ending an epidemic lies in stopping transmission, and the introduction of long-acting PrEP, such as Lenacapavir, could revolutionize HIV prevention efforts. This twice-yearly injectable offers discretion, durability, and dignity, particularly for those facing stigma or criminalization.
The Global Fund’s agreement with Gilead, the manufacturer of Lenacapavir, aims to ensure affordable access to this groundbreaking innovation in low- and middle-income countries. The goal is to make Lenacapavir available to 2 million people within the next three years, supporting rapid and equitable rollout through collaboration with countries, communities, and partners.
However, ensuring that biomedical innovations reach those who need them most is crucial. With 70% of new HIV infections occurring among key populations, addressing barriers to access is paramount. Communities must be empowered to take the lead in HIV prevention efforts, as their involvement has shown to improve outcomes significantly.
Moreover, reducing new infections is vital for the long-term sustainability of HIV responses. Countries need to transition towards nationally owned and financed HIV programs, ensuring self-reliance and continuity in the fight against HIV/AIDS. Lenacapavir plays a critical role in this sustainability strategy, along with supporting countries in building resilient health systems for the future.
Cutting funding for prevention would not only prolong the AIDS pandemic but also delay the transition away from external support. Ending AIDS is a cost-effective goal, with every dollar invested in prevention saving seven dollars in treatment and care costs. It is not just a technical challenge but a test of values – ensuring equal access to lifesaving services for all individuals regardless of their background.
The first generation without AIDS is not just a dream but a choice we must make now. It requires urgency, clarity, and courage to end the epidemic and ensure a future free of HIV/AIDS. History will not remember how well we managed AIDS but whether we had the courage to end it.
